PVCT - Provectus inks option deal with university for antimicrobial device's use for eye infections

• Provectus ( OTC:PVCT ) said it signed an option agreement with the University of Miami (UM) for an exclusive worldwide license of intellectual property (IP) of a photodynamic antimicrobial therapy (PDAT) medical device.
• Provectus intends to use the IP — developed by the Ophthalmic Biophysics Center (OBC) of Bascom Palmer Eye Institute (BPEI), which is part of the UM Health System —  of the PDAT medical device in combination with the company's pharmaceutical-grade rose bengal to treat bacterial, fungal, and viral infections of the eye.
• Provectus also started a sponsored research program with OBC to investigate rose bengal for treating infectious keratitis, the company said in a Sept. 21 press release.

For further details see: